Medeze Group PCL

MEDEZE · BK · Healthcare / Medical Care Facilities

5.70THB-0.05 (-0.87%)

Price History

Full chart

Market Stats

Previous Close5.75

Open5.90

Day Range5.50 – 5.90

52-Week Range5.92 – 7.25

Volume583.30K

Market Cap6.51B

P/E (TTM)46.92

Forward P/E21.98

EPS0.13

Dividend Yield3.93%

50-Day Avg6.44

200-Day Avg6.34

About

Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, Philippines, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells. In addition, the company is involved in research, develops, and collects data on all types of human cellular activities and medical laboratory tests. Further, the company sells dietary supplements, cosmetics, and dermo cosmetics. Medeze Group Public Company Limited was founded in 2010 and is based in Nakhon Pathom, Thailand.

Company Details

SectorHealthcare
IndustryMedical Care Facilities
CEODr. Veerapol Khemarangsan
Employees0
Headquarters28/9 Moo 8, Nakhon Pathom, Thailand, 73220, Thailand
Websitehttps://www.medezegroup.com

Leadership

Dr. Veerapol KhemarangsanCo-Founder, CEO & Director
Associate Prof. Rangsun ParnpaiCo-founder
Dr. Chumrus SakulpaisalCo-founder
Ms. Phunurai AkkarasacksakunCOO & Director
Dr. Tanut Kunkanjanawan Ph.D.Chief Laboratory Officer & Director
Dr. Rachanee O-charoenChief Medical Officer & Director
Ms. Danita PhithaknetikunChief Business Development Officer & Director

Financials

Income Statement

Currency: THB	2023-12-31	2024-12-31	2025-12-31
Total Revenue	701.81M	829.21M	743.65M
Growth (%)	-	+18.15%	-10.32%
Cost of Revenue	151.59M	180.94M	196.32M
Gross Profit	550.22M	648.27M	547.32M
Gross Margin	78.40%	78.18%	73.60%
Operating Expense	245.86M	284.53M	319.01M
Operating Income	304.36M	363.74M	228.31M
Operating Margin	43.37%	43.87%	30.70%
EBITDA	331.86M	412.62M	287.84M
EBITDA Margin	47.29%	49.76%	38.71%
Net Income	239.57M	338.74M	196.38M
Net Income Margin	34.14%	40.85%	26.41%
R&D	15.67M	13.46M	17.30M
R&D as % of Total Revenue	2.23%	1.62%	2.33%
Interest Expense	15.42M	18.42M	22.00M
Interest Expense % of Total Revenue	2.20%	2.22%	2.96%

Balance Sheet

Currency: THB	2023-12-31	2024-12-31	2025-12-31
Total Assets	1.02B	3.43B	3.48B
Total Liabilities	444.22M	506.18M	565.02M
Total Equity	574.99M	2.92B	2.91B
Cash	183.34M	896.70M	1.26B

Cash Flow

Currency: THB	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	347.90M	326.84M	167.23M
Financing Cash Flow	-101.59M	2.00B	-180.63M
Capital Expenditure	51.50M	294.27M	184.34M
Free Cash Flow	296.41M	32.58M	-17.11M
Dividends Paid	270.00M	333.42M	170.82M
FCF to OCF	85.20%	9.97%	-10.23%
Dividend Paid to FCF	91.09%	1023.51%	-998.22%

Earnings

Report Date	Nov 11, 2024	Mar 3, 2025	May 13, 2025	Aug 13, 2025	Nov 18, 2025	Mar 9, 2026	May 13, 2026	Aug 19, 2026
EPS Estimate	0.09	-	-	-	-	-	-	-
EPS Actual	0.12	0.09	0.07	0.05	0.03	0.03	0.03	0.04
Surprise	33.33%	-	-	-	-	-	-	-
Timing	After-hours	-	Pre-market	-	-	-	-	-

Key Statistics & Ratios

Market Cap6.51B

Enterprise Value5.03B

Trailing P/E46.92

Forward P/E21.98

Price / Sales9.12

Price / Book2.23

EPS0.13

Book Value2.76

Revenue (TTM)714.44M

Gross Profit (TTM)528.64M

EBITDA209.73M

Profit Margin19.81%

Operating Margin26.70%

Return on Equity4.79%

Return on Assets3.10%

Shares Outstanding1.07B

Shares Float245.83M

Dividend Yield3.93%

Dividend Rate0.24

Payout Ratio120.75%

Dividends

20261×

0.08Apr 29, 2026

20252×

0.08Nov 21, 20250.08May 6, 2025

20241×

0.08Nov 26, 2024